Saturday 17 October 2026
Export KYNB’s income statement to Excel — free account
Kyntra Bio Inc
KYNB Healthcare Biotechnology
In the quarter to June 2026, revenue fell 209.4%, EPS grew 257.5% and free cash flow fell 131.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
4.85
0.51
−9.51%
Follow KYNB
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.19 |
Piotroski F-Score |
5 | 3 | 4 | 3 | 3 | 2 | 1 | 2 | 2 | 5 |
Altman Z-Score |
1.89 | 5.53 | 6.23 | 6.44 | 3.85 | (1.39) | (3.07) | (8.08) | (14.08) | (20.33) |
P/S ratio |
7.30 | 28.25 | 18.27 | 14.48 | 18.90 | 5.53 | 10.61 | 1.73 | 1.79 | 5.51 |
Altman Z″-Score (non-manufacturers) |
(0.54) | 3.31 | 2.74 | 2.65 | 0.50 | (5.28) | (9.28) | (17.85) | (32.01) | (45.38) |
P/FCF ratio |
228.22 | 0.00 | 0.00 | 0.00 | 42.94 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Beneish M-Score |
(3.60) | (3.19) | 2.29 | (2.67) | (3.66) | (1.66) | (3.87) | (3.39) | (3.55) | (4.57) |
P/Operating CF |
(72.07) | (3,120.12) | (222.75) | (82.48) | (461.08) | (23.69) | (28.42) | (4.41) | (1.74) | (1.94) |
P/B ratio |
7.63 | 6.76 | 7.36 | 6.94 | 7.55 | 5.68 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Tangible BV |
7.63 | 6.76 | 7.36 | 6.94 | 7.55 | 5.68 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
6.44 | 23.38 | 15.81 | 12.60 | 15.23 | 4.31 | 8.37 | (0.83) | 2.95 | 14.55 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.12 | 0.00 | 0.00 |
EV/Operating CF |
166.10 | (46.04) | (44.21) | (41.08) | 32.90 | (12.33) | (8.07) | 0.12 | (0.63) | (19.62) |
EV/FCF |
201.61 | (40.83) | (40.08) | (38.28) | 34.60 | (9.02) | (6.38) | 0.12 | (0.64) | (19.47) |
Quick Ratio |
4.05 | 8.66 | 7.69 | 5.47 | 4.46 | 1.87 | 1.60 | 0.96 | 0.38 | 3.05 |
Current Ratio |
4.09 | 8.71 | 7.75 | 6.84 | 4.63 | 2.10 | 1.80 | 1.52 | 1.47 | 3.39 |
Net Debt/EBITDA |
3.78 | 5.83 | 6.40 | 6.94 | 3.90 | 1.10 | 1.13 | 0.41 | (0.15) | 1.97 |
Debt/Assets |
20.73% | 10.88% | 12.26% | 4.39% | 3.07% | 13.75% | 15.84% | 16.98% | 34.07% | 0.00% |
Debt/Equity |
0.56 | 0.18 | 0.20 | 0.07 | 0.06 | 0.46 | (65.30) | (0.39) | (0.36) | 0.00 |
Asset Turnover |
0.39 | 0.19 | 0.24 | 0.30 | 0.21 | 0.29 | 0.20 | 0.09 | 0.09 | 0.04 |
Operating CF/Net income |
(0.12) | 0.55 | 0.88 | 1.02 | (0.43) | 0.28 | 0.50 | 1.11 | 2.90 | (0.03) |
Capex/Depreciation |
(0.14) | (1.07) | (1.20) | (0.32) | (0.18) | (1.75) | (3.17) | (0.52) | 0.77 | (0.06) |
Interest Coverage |
(4.67) | (12.08) | (7.89) | (31.05) | (79.88) | (268.40) | (209.05) | (39.87) | (18.24) | (5.24) |
| (31.22%) | (33.44%) | (16.06%) | (14.47%) | (38.76%) | (86.50%) | (258.01%) | 307.01% | 24.48% | (165.18%) | |
| (12.35%) | (17.67%) | (9.71%) | (8.86%) | (22.48%) | (36.24%) | (42.44%) | (55.00%) | (14.91%) | 109.81% | |
ROIC |
(162.20%) | 0.00% | (360.67%) | (142.19%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(17.86%) | (15.25%) | (11.87%) | (11.98%) | (30.26%) | (104.76%) | (122.42%) | (239.50%) | (75.28%) | 262.71% |
Average Days of Receivables |
20.82 | 23.55 | 109.15 | 40.48 | 86.70 | 26.99 | 42.27 | 39.94 | 5.93 | 12.24 |
Research and Development Expense of Revenue |
102.19% | 150.02% | 110.74% | 81.56% | 143.45% | 164.48% | 210.89% | 569.35% | 323.05% | 365.17% |
Selling, General and Administrative Expense of Revenue |
25.12% | 39.51% | 29.96% | 52.80% | 60.35% | 52.66% | 88.60% | 184.78% | 166.54% | 430.26% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
17.54% | 28.66% | 24.48% | 25.83% | 41.24% | 30.24% | 46.61% | 108.47% | 85.13% | 102.11% |
Graham Net Nets |
(0.02) | 0.11 | 0.09 | 0.10 | 0.11 | (0.05) | (0.08) | (3.41) | (4.21) | (1.06) |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 26.43 | 278.89 | 117.64 | 0.00 |
Earnings Yield |
(4.60%) | (3.39%) | (2.23%) | (2.05%) | (5.72%) | (22.27%) | (19.69%) | (352.50%) | (90.57%) | 517.88% |
Free Cash Flow Yield |
0.44% | (2.03%) | (2.16%) | (2.27%) | 2.33% | (8.63%) | (12.37%) | (393.35%) | (258.77%) | (13.56%) |
Revenue per Share |
72.99 | 44.87 | 63.33 | 74.04 | 49.06 | 63.70 | 37.60 | 12.03 | 7.40 | 1.59 |
Operating CF per Share |
2.83 | (22.78) | (22.65) | (22.71) | 22.70 | (22.26) | (38.99) | (80.94) | (34.48) | (1.18) |
Capex per Share |
(0.50) | (2.91) | (2.33) | (1.66) | (1.11) | (8.17) | (10.35) | (0.65) | 0.19 | (0.01) |
Free Cash Flow per Share |
2.33 | (25.69) | (24.98) | (24.37) | 21.59 | (30.43) | (49.33) | (81.59) | (34.29) | (1.19) |
Cash per Share |
100.88 | 252.00 | 184.80 | 154.03 | 191.01 | 109.69 | 112.74 | 52.27 | 12.61 | 22.01 |
Shareholders Equity per Share |
69.77 | 187.61 | 157.17 | 154.50 | 122.82 | 62.02 | (0.40) | (47.19) | (51.25) | (4.21) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
69.77 | 187.61 | 157.17 | 154.50 | 122.82 | 62.02 | (0.40) | (47.19) | (51.25) | (4.21) |
Free Cash Flow |
5.86 | (75.01) | (83.98) | (84.46) | 77.61 | (112.42) | (184.67) | (317.54) | (137.22) | (4.81) |
Working Capital |
201.39 | 663.01 | 600.98 | 599.75 | 591.92 | 248.56 | 219.26 | 113.89 | 63.20 | 69.83 |
Capital Expenditures |
(1.25) | (8.49) | (7.84) | (5.75) | (3.99) | (30.19) | (38.73) | (2.52) | 0.78 | (0.04) |
Net Current Asset Value |
(27.93) | 398.06 | 337.89 | 380.50 | 369.72 | (70.65) | (118.74) | (275.65) | (223.13) | (37.53) |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.12 | 0.00 | 0.00 |
Capex to Sales |
0.01 | 0.06 | 0.04 | 0.02 | 0.02 | 0.13 | 0.28 | 0.05 | (0.03) | 0.01 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.07 | 0.06 | 0.05 | 0.42 | 0.66 | 0.61 | 0.59 | 1.02 | 0.00 | 0.00 |
Cash ROIC |
1.11% | (5.43%) | (6.68%) | (7.63%) | 6.73% | (15.18%) | (35.71%) | (346.26%) | 168.28% | (6.69%) |
Accounts Receivable Turnover |
14.17 | 13.86 | 5.90 | 5.57 | 5.01 | 7.94 | 8.35 | 4.37 | 10.58 | 18.48 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.15 | 0.57 | 0.51 | 0.71 | 0.17 | 1.49 | 0.13 |
Inventory Turnover |
— | — | — | 0.10 | 0.76 | 0.54 | 0.57 | 0.14 | 1.53 | 0.16 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 1,937.33 | 1,020.18 | 740.07 | 553.58 | 1,453.55 | 118.78 | 2,458.50 |
Days of Inventory on Hand |
— | — | — | 2,191.59 | 680.29 | 879.53 | 727.77 | 1,582.07 | 74.00 | 2,457.19 |
Average Receivables |
12.93 | 9.45 | 36.07 | 46.07 | 35.17 | 29.64 | 16.85 | 10.71 | 2.80 | 0.35 |
Average Payables |
6.37 | 5.87 | 7.32 | 7.61 | 15.44 | 25.44 | 28.43 | 23.27 | 10.42 | 4.40 |
Average Inventory |
— | — | — | 11.71 | 11.71 | 23.77 | 35.73 | 28.80 | 10.16 | 3.45 |
Average Assets |
470.06 | 684.10 | 889.62 | 869.00 | 842.12 | 800.33 | 691.95 | 516.81 | 319.03 | 167.06 |
Average Common Equity |
185.97 | 361.42 | 538.10 | 531.94 | 488.43 | 335.28 | 113.82 | (92.58) | (194.40) | (111.06) |
Columns are period end dates